Key Takeaways
- CMS confirmed a 2.48% Medicare Advantage payment rate increase for 2027, significantly higher than the 0.09% rate proposed three months earlier.
- Humana (HUM) climbed 12% in after-hours trading, while UnitedHealth (UNH) and CVS Health (CVS) gained more than 6% during premarket sessions.
- The approved rate will channel approximately $13 billion in extra Medicare Advantage funding to health insurers during 2027.
- Other healthcare stocks experienced gains, including Molina Healthcare (MOH) rising 7% and Centene (CNC) advancing 4%.
- Mizuho’s Jared Holz described the rate as “certainly better than the government’s initial rate decision,” while cautioning that the figure remains modest when viewed independently.
Humana (HUM) began Tuesday’s trading session with an approximately 11% gain following Monday evening’s release of the 2027 Medicare Advantage reimbursement rates.
The approved 2.48% rate represents a substantial improvement over January’s proposed 0.09% figure, which surprised industry observers and triggered declines in healthcare insurer equities.
The federal agency’s decision will result in private Medicare insurers receiving over $13 billion in additional government payments throughout 2027.
UnitedHealth (UNH) and CVS Health (CVS), which owns Aetna, both posted premarket gains exceeding 6% on Tuesday. Elevance Health (ELV) advanced approximately 5%. Healthcare providers and managed care companies also experienced positive momentum, with Molina Healthcare (MOH) rising 7% and Centene (CNC) climbing 4%.
The rally in healthcare equities followed intensive advocacy efforts from insurers and industry associations, who contended that January’s proposal failed to account for escalating medical expenses. The Better Medicare Alliance characterized the initial near-zero proposal as effectively a “cut,” emphasizing that medical cost inflation trends range from 7% to 9% annually.
Key Adjustments in the Final Determination
CMS implemented multiple technical modifications accompanying the primary rate figure. Beginning in 2027, the agency will eliminate diagnosis information from unlinked chart review records during risk score calculations, with an exception for beneficiaries transitioning between Medicare Advantage organizations.
The agency indicated this modification will more significantly affect plans that depend extensively on chart reviews to document beneficiary diagnoses and secure elevated reimbursements. CMS additionally refined the Part D risk adjustment framework to reflect modifications introduced by the Inflation Reduction Act.
CMS Administrator Dr. Mehmet Oz stated the revisions seek to maintain “coverage affordable” while guaranteeing patients receive “real value from their plans.”
Financial analysts had maintained conservative expectations ahead of Monday’s disclosure. TD Cowen’s Ryan Langston had projected a more moderate increase in the 1% to 1.5% range. The 2.48% result surpassed those projections, though Mizuho’s Jared Holz offered measured commentary: “We do not believe a Medicare rate increase of 2.5% is so awesome in a vacuum, but is certainly better than the government’s initial rate decision.”
Holz indicated there exists “a chance for margins to expand next year, provided the Companies continue to trim benefits and align costs with revenue.”
Understanding the Rate’s Significance
Medicare Advantage serves approximately 35 million beneficiaries and has experienced consistent expansion, eventually overtaking enrollment in traditional government-administered Medicare. The finalized rate determines how more than half a trillion dollars is distributed through private health insurance plans annually, establishing it as among the most scrutinized metrics in the health insurance industry.
The rate incorporates elements including underlying cost escalation, 2026 Star Ratings affecting quality bonus payments, and risk adjustment methodology refinements. CMS verified it will maintain the 2024 Medicare Advantage risk adjustment framework for 2027.
Bipartisan concerns regarding Medicare Advantage expenditures had introduced additional uncertainty into the determination process. Lawmakers from both parties have questioned insurer documentation practices that can generate elevated payments for patients with more comprehensive recorded diagnoses. The Biden administration’s CMS had already begun restricting those payments, and January’s proposal under the Trump administration indicated that oversight would persist.
